Integra LifeSciences Holdings

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Integra LifeSciences posts solid Q4 results, eyes growth opportunities

Integra LifeSciences delivered strong financial performance in Q4 2022 and full-year 2022, showcasing operational resilience and efficiency amidst supply chain challenges and inflationary pressures.
The company's strategic focus on innovation, international growth, and operational excellence positions it well for sustainable growth in 2023, supported by new product launches and market expansion initiatives.
While facing challenges from supply chain disruptions and inflation, Integra's proactive approach to margin expansion, revenue growth, and strategic investments underscores its commitment to long-term value creation.
With a clear roadmap for 2023, including revenue growth targets, margin improvement strategies, and market expansion plans, Integra is poised to navigate challenges and capitalize on opportunities for continued success.

Integra LifeSciences exceeds Q1 expectations, eyes growth amid challenges

Integra LifeSciences demonstrated resilience and growth potential in Q1 2023, with strong segment performances and strategic initiatives.
While facing challenges like supply constraints and margin pressures, the company remains focused on operational efficiency and growth opportunities.
Reaffirmation of guidance, executive appointments, and proactive strategies position Integra well for future growth and market expansion.
Investors can expect improved performance in the second half, driven by new products, supply chain recovery, and strategic investments.

Integra LifeSciences reports Q2 challenges but shows resilience and growth

Integra LifeSciences navigated challenges from a product recall in Q2, showing resilience with solid profitability and growth in unaffected segments.
The company's strategic focus on returning critical technologies to the market, along with new leadership and financial initiatives, positions it for future success.
Despite challenges, Integra LifeSciences remains confident in regaining market share, sustaining growth momentum, and capitalizing on strategic opportunities.
Operational strengths, market performance, and proactive measures to address challenges underscore the company's resilience and growth potential.

Integra LifeSciences navigates Boston impact, eyes growth opportunities post-remediation

Integra LifeSciences faced challenges from the Boston facility recall but showed resilience with strong performance in key segments. The company is focused on growth opportunities post-Boston remediation and maintains a solid financial position. Analysts are optimistic about the company's ability to recover and grow post-recall.

Integra LifeSciences navigates challenges, eyes global growth opportunities

Integra LifeSciences faced challenges from the Boston recall impacting financials but showcased strengths in strategic product relaunches and divisional growth.
The company's performance metrics for 2023 were mixed, with declines in margins but strong cash flow generation. Opportunities lie in global growth catalysts like CereLink.
Looking ahead, Integra aims for revenue recovery post-Q1 headwinds, emphasizing international expansion and product recovery post-recall.

Integra LifeSciences reports strong Q1 results amidst operational challenges

Integra LifeSciences delivered solid Q1 results driven by revenue growth and successful acquisitions.
While facing challenges with the Boston plant audit and supply constraints, the company is focused on key priorities and opportunities for growth.
Maintaining financial stability with a clear plan to address leverage and uncertainties around product reintroduction.
Investors are closely monitoring the company's progress on key initiatives and leadership transition.

Integra LifeSciences excels in Q2 amidst compliance challenges and growth opportunities

Integra LifeSciences delivered a strong Q2 performance, focusing on operational improvements and compliance enhancements to drive long-term growth and sustainability.
While facing challenges such as revenue impacts from compliance investments and margin pressures, the company remains resilient with a strategic focus on market positioning and efficiency.
With updated guidance, successful acquisition integration, and a CEO search underway, Integra is poised to navigate challenges and capitalize on opportunities for future success.

Integra LifeSciences appoints new CEO amidst revenue challenges in Q3

Integra LifeSciences faced revenue challenges in Q3 2024 due to supply issues and compliance plan implementation. The company announced Mojdeh Poul as the new CEO to drive operational excellence and growth. Despite challenges, revenue diversification and financial stability were maintained, with a focus on future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q3 2019 Results - Earnings Call Transcript

Reported revenues increased 3.6% to $379.1 million; organic revenues increased 4.7%

Integra LifeSciences Reports Third Quarter 2019 Financial Results

Integra recently acquired Rebound Therapeutics, a company that develops visualization- and illumination-based medical devices for use in surgery.

Integra LifeSciences: Innovative Technologies Will Drive Stock Higher

PLAINSBORO, N.J., Sept.  23, 2019  (GLOBE NEWSWIRE) -- During the 18th European Burns Association (EBA) Congress, which took place in Helsinki, Finland, from 4 to 7 September 2019, Integra LifeSciences announced its support for EBA through an educational grant for their “Share your Care” junior exchange program dedicated to surgeons-in-training.

Integra LifeSciences Supports the European Burns Association’s “Share your Care” Educational Program

PLAINSBORO, N.J., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced positive findings from its Cadence® Total Ankle System retrospective study. Tim Daniels, MD, FRCSC, Professor, University of Toronto and lead investigator for this study, reported that patients suffering from end-stage arthritis experienced improvements in quality of life, functional measures, and pain when treated with the Cadence prosthesis.

Integra LifeSciences Presents Cadence® Total Ankle System Retrospective Study Abstract at AOFAS

Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.

Integra Buys Rebound Therapeutics to Boost Neurosurgery Line

Acquisition Adds New, Minimally Invasive Platform for Neurosurgery Acquisition Adds New, Minimally Invasive Platform for Neurosurgery

Integra LifeSciences Acquires Rebound Therapeutics Corporation

Globus Medical

IART vs. GMED: Which Stock Is the Better Value Option?

IART or GMED: Which Is the Better Value Stock Right Now?

Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.

Integra LifeSciences' Organic Growth Strong on New Products

Integra (IART) reported earnings 30 days ago. What's next for the stock?

Why Is Integra (IART) Down 1% Since Last Earnings Report?

PLAINSBORO, N.J., Aug.  21, 2019  (GLOBE NEWSWIRE) --  Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conferences in September:

Integra LifeSciences to participate in the Wells Fargo 2019 Healthcare Conference and the Morgan Stanley 17th Annual Global Healthcare Conference in September 2019

Integra LifeSciences Holdings Corporation (IART) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Integra LifeSciences

We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.

Integra Lifesciences' (IART) Earnings Top Estimates in Q2

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q2 2019 Results - Earnings Call Transcript

Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.

Integra Partners AI-Driven Data Analytics Firm in Wound Care

Integra (IART) Down 4.9% Since Last Earnings Report: Can It Rebound?

Investor confidence is still high on growth prospects of Integra LifeSciences (IART).

Here's Why You Should Hold On to Integra LifeSciences Stock

Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.

Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q1 2019 Results - Earnings Call Transcript

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences (IART) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Integra LifeSciences Holdings Stock (IART)